Eumentis Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Mezzanine

  • Latest Deal Amount
  • $765K

  • Investors
  • 8

Eumentis Therapeutics General Information

Description

Developer of novel therapies designed to treat neuro problems and diseases. The company synthesizes knowledge about established effective therapies with the latest insights into brain function and focuses on neurodevelopmental and neurodegenerative diseases by translating cutting-edge science into patient recovery, enabling the healthcare industry with better biopharmaceutical treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 440 Stevens Avenue
  • Suite 200
  • Solana Beach, CA 92075
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 440 Stevens Avenue
  • Suite 200
  • Solana Beach, CA 92075
  • United States
+1 (617)

Eumentis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eumentis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Mezzanine 26-Jun-2024 $765K Completed Generating Revenue
6. Later Stage VC (Series B) Completed Generating Revenue
5. Early Stage VC 17-Mar-2023 Completed Generating Revenue
4. Grant 08-Feb-2023 Completed Pre-Clinical Trials
3. Early Stage VC 08-Apr-2022 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 27-Oct-2020 $3.9M $3.9M Completed Pre-Clinical Trials
1. Grant 13-Feb-2020 $2M Completed Pre-Clinical Trials
To view Eumentis Therapeutics’s complete valuation and funding history, request access »

Eumentis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Eumentis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eumentis Therapeutics Patents

Eumentis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021231582-A1 Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia Inactive 12-May-2020
EP-4121403-A1 Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections Inactive 19-Mar-2020
EP-4121403-A4 Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections Inactive 19-Mar-2020
US-20230218548-A1 Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections Inactive 19-Mar-2020
WO-2021188864-A1 Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections Inactive 19-Mar-2020 A61P11/00
To view Eumentis Therapeutics’s complete patent history, request access »

Eumentis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eumentis Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
United States Department of War Government
K2X Venture Capital Minority
Rivermount VC Fund Venture Capital Minority
Joyance Partners Venture Capital Minority
Life Science Angels Angel Group Minority
You’re viewing 5 of 8 investors. Get the full list »

Eumentis Therapeutics FAQs

  • When was Eumentis Therapeutics founded?

    Eumentis Therapeutics was founded in 2019.

  • Where is Eumentis Therapeutics headquartered?

    Eumentis Therapeutics is headquartered in Solana Beach, CA.

  • What is the size of Eumentis Therapeutics?

    Eumentis Therapeutics has 8 total employees.

  • What industry is Eumentis Therapeutics in?

    Eumentis Therapeutics’s primary industry is Drug Discovery.

  • Is Eumentis Therapeutics a private or public company?

    Eumentis Therapeutics is a Private company.

  • What is Eumentis Therapeutics’s current revenue?

    The current revenue for Eumentis Therapeutics is .

  • How much funding has Eumentis Therapeutics raised over time?

    Eumentis Therapeutics has raised $13.7M.

  • Who are Eumentis Therapeutics’s investors?

    United States Department of War, K2X, Rivermount VC Fund, Joyance Partners, and Life Science Angels are 5 of 8 investors who have invested in Eumentis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process